Short answer
Tyra Biosciences, Inc. (TYRA) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release announces Tyra Biosciences’ financial results for the quarter ended September 30, 2026.
Tyra Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release announces Tyra Biosciences’ financial results for the quarter ended September 30, 2026
- Investors should review Exhibit 99.1 for reported financial results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Initial SURF302 results showed 79% ORR and 64% BOR CR at 60 mg QD across 14 patients
- Single-lesion patients delivered 100% ORR and 75% BOR CR, supporting planned Phase 3 adjuvant development in 2027
- $400 million financing increased cash, equivalents and securities to $700.5 million, funding planned operations through 2030
- Q3 R&D rose to $43.1 million from $25.5 million, reflecting expanded dabogratinib trials and development spending
- Q3 net loss widened to $51.1 million from $29.9 million, with loss per share increasing to $0.74 from $0.50
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tyra Biosciences, Inc. 8-K filings
Get the next TYRA 8-K as it lands
Follow TYRA for push alerts, or ask the research agent what this filing means.